Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics | Neuropsychopharmacology
Neuropsychopharmacology
Nanoparticle delivery systems for substance use disorder | Neuropsychopharmacology
Volume 47 Issue 12, November 2022
Chris Allen (@ChrisPGAllen) / Twitter
Neuropsychopharmacology - ACNP
Neuropsychopharmacology
Deciphering impact factors | Nature Neuroscience
Addiction as a brain disease revised: why it still matters, and the need for consilience | Neuropsychopharmacology
Neuropsychopharmacology
How Placebos Change the Patient's Brain | Neuropsychopharmacology
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits | Nature Reviews Neurology
Neuropsychopharmacology Reviews - ACNP
New Impact Factor of “Pharmacological Reports” = 3,919 (JCR 2021) - Institute of Pharmacology - Polish Academy of Sciences
Neuropsychopharmacology
Neuropsychopharmacology
Neuropsychopharmacology Template - Nature
Development of prefrontal cortex | Neuropsychopharmacology
Signalling from the periphery to the brain that regulates energy homeostasis | Nature Reviews Neuroscience
The environment and schizophrenia | Nature
The Genetics of Stress-Related Disorders: PTSD, Depression, and Anxiety Disorders | Neuropsychopharmacology
What's wrong with my experiment?: The impact of hidden variables on neuropsychopharmacology research | Neuropsychopharmacology
Neuropsychopharmacology Template - Nature
Major depressive disorder | Nature Reviews Disease Primers
Associations between dimensions of behaviour, personality traits, and mental-health during the COVID-19 pandemic in the United Kingdom | Nature Communications
